(90 days)
The BSM-1101 and BSM-1102 Pattern Monitors are intended for medical purposes to measure the heart rate from a signal produced by an electrocardiograph. The devices sound an alarm when the heart rate falls outside preset upper and lower limits. The devices include an oximeter used to transmit radiation at a known wavelength through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. The devices include a noninvasive blood pressure measurement system that provides a signal from which systolic, diastolic, and mean pressures can be derived through the use of pressure cuffs placed on the arm, leg or finger. The devices may be used as a radio frequency physiological signal transmitter to condition physiological signals so that they can be transmitted via radio frequency from one location to another, e.g. a central monitoring station.
Common names for the BSM-1102 include Patient Monitor, Portable Monitor, Transport Monitor, Cardiac Monitor and Bedside Monitor. Nihon Kohden's BSM-1101 and BSM-1102 Patient Monitors are intended for medical purposes to measure the heart rate from a signal produced by an electrocardiograph. These devices sound an alam when the heart rate falls outside oreset upper and lower limits. The devices include an oximeter used to transmit radiation at a known wavelenath through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. These devices include a noninvasive blood pressure measurement system that provides a signal from which systolic, and mean pressures can be derived through the use of pressure cuffs placed on the arm, leg or finger. The devices may be used as a radio frequency physiological signal transmitter to condition physiological signals so that they can be transmitted via radio frequency from one location to another, e.g. a central monitoring station.
The provided text describes the Nihon Kohden BSM-1101 and BSM-1102 Patient Monitors and their clearance via a 510(k) premarket notification (K973918). However, it does not contain the detailed information necessary to answer all the questions about acceptance criteria and a specific study proving device performance.
The 510(k) summary focuses on demonstrating substantial equivalence to a predicate device (Nihon Kohden BSM-2101A Patient Monitor, K914092), rather than providing a detailed report of a study that establishes specific performance against predefined acceptance criteria for the new devices.
Here's what can be extracted and what is missing:
1. A table of acceptance criteria and the reported device performance
- Acceptance Criteria: Not explicitly stated as numerical values or thresholds in the provided text. The submission focuses on compliance with general testing and equivalence to a predicate.
- Reported Device Performance: The document states that the devices are subjected to "electromagnetic, environmental, safety and performance testing procedures to verify the operation of the device." It also mentions "Software validation tests the operation of the software functions of acquiring, processing, displaying and recording of the device." However, no specific performance metrics (e.g., accuracy, precision for heart rate, SpO2, NIBP) or their results are provided.
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Not specified. The document does not describe a clinical study or a specific test set with sample sizes.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable/Not specified. Ground truth establishment by experts is typically relevant for diagnostic imaging or interpretation tasks, which are not detailed for these patient monitors. The document describes a patient monitor measuring physiological parameters, not interpreting complex medical images.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable/Not specified. Adjudication methods are typically associated with expert review processes for ground truth establishment, which is not detailed here.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No. An MRMC comparative effectiveness study is not mentioned as this device is a patient monitor, not an AI-assisted diagnostic tool for human readers.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- This question is more geared towards AI algorithms. While the device contains algorithms for processing physiological signals, the document does not break down performance into "algorithm only" vs. "human-in-the-loop" in the way this question implies for AI tools. The device's performance is assumed to be its standalone function as a monitor.
- The document implies standalone performance testing through "performance testing procedures" and "Software validation tests the operation of the software functions of acquiring, processing, displaying and recording of the device." However, no specific results are provided.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- Not explicitly stated in detail. For heart rate, SpO2, and NIBP, the "ground truth" would typically be established by highly accurate reference measurement devices or invasive clinical standards (e.g., arterial line for NIBP, co-oximetry for SpO2, ECG for heart rate). The document states "performance testing procedures" were used, but doesn't specify how ground truth was established for these tests.
8. The sample size for the training set
- Not applicable/Not specified. This device is a patient monitor, not an AI/ML model that undergoes a training phase with a specific dataset.
9. How the ground truth for the training set was established
- Not applicable/Not specified. As there is no training set mentioned, this question is not relevant.
In summary:
The provided 510(k) summary is a high-level regulatory document focused on substantial equivalence. It confirms that the devices underwent various types of testing (electromagnetic, environmental, safety, performance, software validation) to verify operation, but it does not disclose the specific methods, sample sizes, acceptance criteria, or performance results from these tests in detail. This level of detail is typically found in design verification and validation reports, which are part of the full 510(k) submission but not usually present in the public summary document.
{0}------------------------------------------------
NIHON KOHDEN AMERICA, INC. October 14, 1997
510(k) NOTIFICATION BSM-1101/BSM-1102 Patient Monitor
JAN 13 1998
SECTION 2 - 510(K) SUMMARY
Name and Address of Applicant
Nihon Kohden America, Inc. Attn: Requiatory Affairs 2601 Campus Drive Irvine, California 92612-1601 (714) 250-3959
These devices have been class II by the Division of Cardiovascular, Respiratory, and Neurological Devices and the Cardiovascular Device Classification Panel under 21 CFR Part 870.2300 Cardiac Monitor (Including cardiotachometer and rate alams) per 74 DRT, 870.2700 Oximeter per 74 DQA, 870.1130 Noninvasive Blood Pressure Measurement System per 74 DXN, and 870.2910 Radio Frequency Physiological Signal Transmitter per 74 DRG
Common names for the BSM-1102 include Patient Monitor, Portable Monitor, Transport Monitor, Cardiac Monitor and Bedside Monitor.
The predicate device is the Nihon Kohden BSM-2101A Patient Monitor per 510(k) #K914092, commercial distribution certification dated May 28, 1992.
Nihon Kohden's BSM-1101 and BSM-1102 Patient Monitors are intended for medical purposes to measure the heart rate from a signal produced by an electrocardiograph. These devices sound an alam when the heart rate falls outside oreset upper and lower limits. The devices include an oximeter used to transmit radiation at a known wavelenath through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. These devices include a noninvasive blood pressure measurement system that provides a signal from which systolic, and mean pressures can be derived through the use of pressure cuffs placed on the arm, leg or finger. The devices may be used as a radio frequency physiological signal transmitter to condition physiological signals so that they can be transmitted via radio frequency from one location to another, e.g. a central monitoring station. These devices will be available for use by medical personnel on all patient populations within a medical facility.
To date, no performance standards or special controls are known or established for these devices as required by Section 514 of the Food, Drug and Cosmetic Act and implemented by 21 CFR Part 861.
The BSM-1101 and BSM-1102 are not intended to be sterile.
The BSM-1101 and BSM-1102 Patient-Monitors were determined to be non-contacting per the Tripartie Guidance. Therefore, good laboratory practice studies were not required per 21 CFR part 58. Accessories manufactured.by .Nihon-Kohden-that .max .contact the .patientinclude-TL-101T, .- TL-120T, TL-121T, TL-051S, TL-052S, TL-061S and TL-062S SpO2 probes. The TL-101T, TL-120T and TL-121T SpO2 problement accessories submitted for review in a separate 510/k) submission. The TL-0515, TL-052S, TL-061S and TL-062S SpO2 probes were previously submitted as accessories to the ZB-831PA Telemetry Transmitter, per 510(k) #K946175, commercial distribution certification dated November 22, 1995.
The BSM-1101 and BSM-1102 Patient Monitors are subjected to electromagnetic, environmental, safety and performance testing procedures to verify the operation of the device. Software validation tests the operation of the software functions of acquiring, processing, displaying and recording of the device.
Based on the above, Nihon Kohden believes that the BSM-1101 and BSM-1102 Patient Monitors are substantially equivalent to the Nihon Kohden BSM-2101A Patient Monitor.
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it, often used as a symbol of medicine. The caduceus is positioned to the right of the text, which reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement around the logo.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20856
JAN 1 3 1998
Mr. Gary Reasoner Director of Product Operations Nihon Kohden America, Inc. 2601 Campus Drive Irvine, CA 92715
K973918 Re : Nihon Kohden BSM-1101 and BSM-1102 Patient Monitor Trade Name: Requlatory Class: II (two) 74 DRT Product Code: Dated: October 14, 1997 Received: October 15, 1997
Dear Mr. Reasoner:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: "General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{2}------------------------------------------------
Page 2 - Mr. Gary Reasoner
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neuroloqical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
G. Indications for Use Statement
510(k) Number (if known):
Device Name: BSM-1101 and BSM-1102 Patient Monitor
Indications for Use:
The BSM-1101 and BSM-1102 Pattern Monitors are intended for medical purposes to measure the heart rate from a signal produced by an electrocardiograph. The devices sound an alarm when the heart rate falls outside preset upper and lower limits. The devices include an oximeter used to transmit radiation at a known wavelength through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. The devices include a noninvasive blood pressure measurement system that provides a signal from which systolic, diastolic, and mean pressures can be derived through the use of pressure cuffs placed on the arm, leg or finger. The devices may be used as a radio frequency physiological signal transmitter to condition physiological signals so that they can be transmitted via radio frequency from one location to another, e.g. a central monitoring station.
The BSM-1101 and BSM-1102 Patient Monitors will be available for use by medical personnel on all patient populations within a medical facility.
Prescription Use
(Per 21 CFR 801.109)
Qouglas Killeen
(Division Sign-Off)
Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).